传染病药物发展

揭示未满足的传染病的解决方案。

  • 访问我们的病毒,细菌,真菌和寄生虫病和疫苗发育的全球经验。

  • 通过我们综合的临床前和临床调查结果加速您的传染病计划。yaboapp体育官网

  • Capitalize on unique insights from more than 150 infectious disease studies with over 17,000 patients.

Infectious Disease Education Center at Covance
Covance偏好中心
您的需求

Today, unmet needs are driving global demand for safer, more robust and efficacious infectious disease drugs. Unfortunately, many factors challenge the discovery of global solutions — factors like global mobility, the rapid emergence of antibiotic resistance and the rise of hospital acquired infections. Our successful experience in developing infectious disease solutions leverage unique thinking and capabilities that span preclinical and clinical capabilities across the areas of bacterial, viral, fungal and parasitic diseases. In fact, we’ve worked on more than 150 infectious disease studies — including three of the last four antibiotics approved — and leverage this expertise to shape new opportunities for you.

从选择最合适的动物模型系统来获取有关疫苗抗原的免疫原性的信息,以确定对疫苗成功至关重要的特征,我们确保您的分子监管提交是声音。而且,如果您需要使用综合实验室和微生物学服务的大型全球试验的快速项目启动,我们拥有专业知识,以迅速地兑您的关键里程碑。

  • 获取验证的股票表征良好的传染性攻击剂,以评估预防性和治疗疫苗和抗感染性

  • 利用我们的重要BSL-1和BSL-2遏制设施,这些设施是Aaalac-Concredited,USDA注册和糖醛保证

  • 开发运输解决方案,准备定制麦克风,以测试新研究药物的易感性

Hepatitis C is a significant medical challenge that we’re actively partnering to cure. With research rapidly advancing and new treatment paradigms the competitive landscape of new drugs in development requires rapid testing to provide both medical and economic proof of efficacy. In addition, we have successfully brought multiple influenza and HIV solutions to market. From genomics to clinical development to safety and viral testing in our central laboratories, we are relentless in our promise to provide you guidance and help deliver solutions made real.

Our Integrated Services

我们为您的传染病发展提供全面的服务套件。从临床前免yaboapp体育官网疫学研究到概念证明对全球临床试验,我们的目标是利用我们的巨大科学和运营经验。我们尽早整合我们的服务,帮助您最大限度地提高您的学习行为 - 以及您的分子的投资回报率。